New search | Conferencedetail
Print view

Head and Neck Cancer Drug Development Summit

Evvnt Promotion / evvnt
30.11.2021 - 01.12.2021  Virtual
Time: 09:00 to 15:00
Conference themes
The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the head and neck cancer space has entered the most active period to date, with emerging immunotherapy biotechs, leading biopharma companies, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need.
Professional congress organizer (PCO)
Hanson Wade

Speakers: Lars Birgerson, Chief Executive Officer, Adlai Nortye, Sophia Randolph, Chief Medical Officer, Alexo Therapeutics Inc., Michael Needle, Chief Medical Officer, AVEO Oncology, and more.

Enquiries and Registration:
Mr. Customer Service
Congress fees
Industry Rate - Early Bird 1 Pricing (save $500): USD 1599.00, Industry Rate - Final Price: USD 2099.00, Solution Provider Rate - Early Bird 1 Pricing (save $700): USD 1899.00, Solution Provider Rate - Final Price: USD 2599.00
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Hilfswerk AustriaOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation newTreeÖsterreichische Akademie der ÄrzteEuropean Health Forum GasteinÖsterreichisches Rotes KreuzAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÖsterreichische Gesellschaft für Public Health